Pfizer vaccine lowers risk of inflammatory condition in teens: CDC
The Pfizer-BioNTech COVID-19 vaccine dramatically reduces the risk of teenagers developing MIS-C, a dangerous inflammatory condition, according to a new study from the Centers for Disease Control and Prevention published Friday.
MIS-C is a condition in which different body parts can become inflamed such as the heart, lungs and kidneys. It tends to appear in kids and adolescents two to six weeks after becoming infected with COVID-19.
![](https://s.abcnews.com/images/Health/covid-vaccine-teen-01-gty-jef-210713_1626205611043_hpMain.jpg)
Researchers looked at children and teens between ages 12 and 18 from 24 hospitals across the country.
They found that the vaccine was 91% against MIS-C. Of the children who were critically ill with MIS-C and required life support, all were unvaccinated.
"No fully vaccinated patients with MIS-C required respiratory or cardiovascular life support, as opposed to 39% of unvaccinated MIS-C patients who did," the authors wrote.
-ABC News' Sony Salzman